ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO903

Circulating Interferon-λ3, HBV Vaccination, and HBV/HCV Infections in Hemodialysis Patients

Session Information

  • Dialysis: Infection
    November 02, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Dialysis

  • 610 Dialysis: Infection


  • Grzegorzewska, Alicja E., Poznan University of Medical Sciences (PUMS), Poznan, Poland
  • Swiderska, Monika K., PUMS, Poznan, Poland
  • Mostowska, Adrianna, PUMS, Poznan, Poland
  • Jagodzinski, Pawel P., PUMS, Poznan, Poland

Interferon (IFN)-λ3 gene (IFNL3) is known from its crucial role in HCV clearance. Our aim was to investigate circulating IFN-λ3 and single nucleotide polymorphisms (SNPs) of IFNL3 in hemodialysis (HD) patients who differed in response to HBV vaccination and status of HBV/HCV infections.


In 201 HD patients and 28 controls, plasma IFN-λ3 (ng/L) was determined using ELISA. IFNL3 SNPs (rs12979860, rs8099917) were genotyped using HRM analysis.


HBV vaccine responders among HD patients showed higher IFN-λ3 than healthy responders (120, 36–233 vs 62, 12.3–280, P=0.0004). In HD group, significant differences in circulating IFN-λ3 were shown between responders and non-responders to HBV vaccination (120, 36–233 vs 43, 15.9–77.4, P=1.0E-7) as well as between HBsAg positive patients and those who developed anti-HBs and became HBsAg negative after HBV infection (39.1, 10–83.4 vs 125, 35–215, P=0.010). Responders to HBV vaccination, who resolved HCV infection, did not differ in circulating IFN-λ3 from non-infected responders (133, 14.8–400 vs 120, 36–233, P=0.714), whereas responders to HBV vaccination, who did not show spontaneous HCV resolution, revealed lower IFN-λ3 than non-infected responders (74, 4.9–275 vs 120, 36–233, P=0.013). In patients with both infections, HBsAg positive/HCV RNA positive subjects showed lower IFN-λ3 (13.3, 9–21.6) than only HCV RNA positive patients (57.5, 13.7–203, P=0.031) and lower compared with patients who resolved both infections (88.5, 16.0–300, P=0.020). Circulating IFN-λ3 showed independent positive association with anti-HBs titer (β±SE 8.4±1.1, P=4.0E-13) and negative associations with HCV RNA (β±SE -32.5±11.4, P=0.005) and HBsAg (β±SE -45.3±22.9, P=0.049) positivity. Non-responders to HBV vaccination, patients HBsAg positive, and subjects replicating HCV composed a group with unfavorable outcomes. The remaining patients were analyzed as having favorable outcomes. The latter showed higher IFN-λ3 (120, 14.8–400 vs 50.7, 4.9–275, P=1.0E-11), but did not differ in distribution of IFNL3 SNPs compared with subjects with unfavorable outcomes.


Higher IFN-λ3 concentrations are associated with response to HBV vaccination, self-limited HBV infection, and spontaneous HCV resolution.